^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    DRUG:

    Estring (estradiol)

    Associations

    News

    Trials
    Company:
    Pfizer
    Drug class:
    Estrogen receptor agonist
    Related drugs:
    Associations

    News

    Trials
    6ms
    Palbociclib combined with endocrine treatment in hormone receptor-positive, HER2-negative breast cancer patients with high relapse risk after neoadjuvant chemotherapy: subgroup analyses of premenopausal patients in PENELOPE-B. (PubMed, ESMO Open)
    In premenopausal women, who received tamoxifen plus OFS as ET, the addition of palbociclib to ET results in a favorable iDFS. The safety profile seems favorable and in contrast to chemotherapy palbociclib does not impact OF throughout the treatment period.
    Journal
    |
    HER-2 (Human epidermal growth factor receptor 2) • ER (Estrogen receptor)
    |
    Ibrance (palbociclib) • tamoxifen • Estring (estradiol)
    8ms
    Adherence to Vaginal Estrogen Therapy in Hypoestrogenic Women With Recurrent Urinary Tract Infections (clinicaltrials.gov)
    P4, N=111, Recruiting, University of California, Irvine
    New P4 trial • Adherence
    |
    Estring (estradiol)
    almost2years
    Estradiol and Estrone Have Different Biological Functions to Induce NF-κB-Driven Inflammation, EMT and Stemness in ER+ Cancer Cells. (PubMed, Int J Mol Sci)
    This work demonstrates that E1 and E2 have different biological functions in ER+ gynaecologic cancers. These results open a new line of research in the study of ER+ cancer subtypes, highlighting the potential key oncogenic role of E1 and HSD17B E1-synthesizing enzymes in the development and progression of these diseases.
    Journal
    |
    ER (Estrogen receptor)
    |
    ER positive
    |
    Estring (estradiol)
    3years
    Estradiol Levels in Patients Treated With Estring (clinicaltrials.gov)
    P2, N=14, Completed, University of Arizona | N=10 --> 14
    Clinical • Enrollment change
    |
    ER (Estrogen receptor)
    |
    ER positive
    |
    Estring (estradiol)
    5years
    NSABP FB-13: An assessment of the biological and clinical effects of palbociclib with ovarian suppression and letrozole in the neoadjuvant treatment of pts (pts) with premenopausal (preM) estrogen-receptor positive/HER2-negative primary breast cancer (SABCS 2019)
    A 4-wk estradiol level in the postmenopausal range will be required to receive further treatment...Present accrual and target accrual: Currently 12 of a planned 76 pts have been enrolled. NSABP Operations contact information: Diana Gosik, Diana.Gosik@nsabp.org NCT03628066 SUPPORT: Genomic Health Inc, Pfizer, NSABP Foundation
    Clinical
    |
    HER-2 (Human epidermal growth factor receptor 2) • ER (Estrogen receptor)
    |
    Ibrance (palbociclib) • letrozole • goserelin acetate • Estring (estradiol)